NEW YORK (dpa-AFX Broker) - The analyst firm Jefferies has raised its target price for Schott Pharma from 30.40 to 34.30 euros after the annual figures and left its rating at "Hold". Analyst James Vane-Tempest raised his sales estimates in a study published on Wednesday. However, he revised his forecasts for the operating result slightly downwards, as he anticipates a further reduction in inventories. In addition, investments in production are unlikely to be fully offset by optimization measures./gl

/zb

Publication of the original study: 30.01.2024 / 07:39 / ET First transmission of the original study: 30.01.2024 / 19:00 / ET

-----------------------

dpa-AFX Broker - the Trader News from dpa-AFX

-----------------------